Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Non-Hydroxamate Zinc-Binding Groups as Warheads for Histone Deacetylases
Anton Frühauf, Franz‐Josef Meyer‐Almes
Molecules (2021) Vol. 26, Iss. 17, pp. 5151-5151
Open Access | Times Cited: 31

Showing 1-25 of 31 citing articles:

Advances in targeting histone deacetylase for treatment of solid tumors
Mu-Qi Shi, Ying Xu, Xin Fu, et al.
Journal of Hematology & Oncology (2024) Vol. 17, Iss. 1
Open Access | Times Cited: 31
Exploring Alternative Zinc-Binding Groups in Histone Deacetylase (HDAC) Inhibitors Uncovers DS-103 as a Potent Ethylhydrazide-Based HDAC Inhibitor with Chemosensitizing Properties
Daniel Stopper, Lukas Biermann, P. R. Watson, et al.
Journal of Medicinal Chemistry (2025)
Closed Access | Times Cited: 2
Selective HDAC3 Inhibitors with Potent In Vivo Antitumor Efficacy against Triple-Negative Breast Cancer
Sravani Pulya, Ambati Himaja, Milan Paul, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 17, pp. 12033-12058
Closed Access | Times Cited: 30
Development of the first non-hydroxamate selective HDAC6 degraders
Tim Keuler, Beate König, Nico Bückreiß, et al.
Chemical Communications (2022) Vol. 58, Iss. 79, pp. 11087-11090
Closed Access | Times Cited: 29
Selectivity of Hydroxamate- and Difluoromethyloxadiazole-Based Inhibitors of Histone Deacetylase 6 In Vitro and in Cells
J. Ptáček, Ivan Šnajdr, Jiří Schimer, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 5, pp. 4720-4720
Open Access | Times Cited: 17
Development and Pharmacochemical Characterization Discover a Novel Brain-Permeable HDAC11-Selective Inhibitor with Therapeutic Potential by Regulating Neuroinflammation in Mice
Ping Bai, Yan Liu, Liuyue Yang, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 23, pp. 16075-16090
Closed Access | Times Cited: 17
Discovery of HDAC6, HDAC8, and 6/8 Inhibitors and Development of Cell-Based Drug Screening Models for the Treatment of TGF-β-Induced Idiopathic Pulmonary Fibrosis
Wei-Chieh Yu, T.Y. Yeh, Chih-Hung Ye, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 15, pp. 10528-10557
Closed Access | Times Cited: 15
Selective and Bioavailable HDAC6 2-(Difluoromethyl)-1,3,4-oxadiazole Substrate Inhibitors and Modeling of Their Bioactivation Mechanism
Lena Ripa, Jenny Sandmark, Glyn A. Hughes, et al.
Journal of Medicinal Chemistry (2023) Vol. 66, Iss. 20, pp. 14188-14207
Closed Access | Times Cited: 15
Hydrazides as Inhibitors of Histone Deacetylases
María do Carmo Carreiras, José Marco‐Contelles
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 16, pp. 13512-13533
Closed Access | Times Cited: 5
Comprehensive Mechanistic View of the Hydrolysis of Oxadiazole-Based Inhibitors by Histone Deacetylase 6 (HDAC6)
L. Motlova, Ivan Šnajdr, Zsófia Kutil, et al.
ACS Chemical Biology (2023) Vol. 18, Iss. 7, pp. 1594-1610
Open Access | Times Cited: 11
Quinazoline‐chalcone hybrids as HDAC/EGFR dual inhibitors: Design, synthesis, mechanistic, and in‐silico studies of potential anticancer activity against multiple myeloma
Mostafa A. Mansour, Asmaa M. AboulMagd, Samar H. Abbas, et al.
Archiv der Pharmazie (2024) Vol. 357, Iss. 5
Closed Access | Times Cited: 4
Bayesian Optimization over Multiple Experimental Fidelities Accelerates Automated Discovery of Drug Molecules
Matthew A. McDonald, Brent A. Koscher, Richard B. Canty, et al.
ACS Central Science (2025) Vol. 11, Iss. 2, pp. 346-356
Open Access
Discovery and evaluation of novel Benzohydroxamic acid-indole derivatives as dual inhibitors of ADAM17 and HDAC2 with antitumor activity
Xiaoxuan Song, Xin Tong, Kaisi Yang, et al.
Bioorganic Chemistry (2025) Vol. 157, pp. 108308-108308
Closed Access
Discovery of Potential Selective HDAC8 Binders: Using Combination of Pharmacophore‐Based–Structure‐Based Virtual Screening, ADME Filtration, and Molecular Dynamics Studies
Debashis Roy Chowdhury, Debanjan Sen, S. Roy, et al.
ChemistrySelect (2025) Vol. 10, Iss. 15
Closed Access
Exploring putative histone deacetylase inhibitors with antiproliferative activity of chrysin derivatives
Thitiporn Kamloon, Thanaset Senawong, Gulsiri Senawong, et al.
Medicinal Chemistry Research (2025)
Closed Access
Drug Discovery for Histone Deacetylase Inhibition: Past, Present and Future of Zinc-Binding Groups
Gustavo Salgado Pires, Heber Victor Tolomeu, Daniel A. Rodrigues, et al.
Pharmaceuticals (2025) Vol. 18, Iss. 4, pp. 577-577
Open Access
First Fluorescent Acetylspermidine Deacetylation Assay for HDAC10 Identifies Selective Inhibitors with Cellular Target Engagement**
Daniel Herp, Johannes Ridinger, Dina Robaa, et al.
ChemBioChem (2022) Vol. 23, Iss. 14
Open Access | Times Cited: 16
In the quest for histone deacetylase inhibitors: current trends in the application of multilayered computational methods
Abdullahi İbrahim Uba, Gökhan Zengin
Amino Acids (2023) Vol. 55, Iss. 12, pp. 1709-1726
Closed Access | Times Cited: 7
Enterocyte-specific deletion of metal transporter Zip14 (Slc39a14) alters intestinal homeostasis through epigenetic mechanisms
Felix R. Jimenez, Courtney H. Ruggiero, Kelley Lobean McKinley, et al.
AJP Gastrointestinal and Liver Physiology (2022) Vol. 324, Iss. 3, pp. G159-G176
Open Access | Times Cited: 12
Uracil as a Zn-Binding Bioisostere of the Allergic Benzenesulfonamide in the Design of Quinoline–Uracil Hybrids as Anticancer Carbonic Anhydrase Inhibitors
Samar El‐Kalyoubi, Ehab S. Taher, Tarek S. Ibrahim, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 494-494
Open Access | Times Cited: 11
Rational design of metabolically stable HDAC inhibitors: An overhaul of trifluoromethyl ketones
Riddhidev Banerjee, Endri Karaj, Sabitri Lamichhane, et al.
European Journal of Medicinal Chemistry (2022) Vol. 244, pp. 114807-114807
Open Access | Times Cited: 8
FLT3-PROTACs for combating AML resistance: Analytical overview on chimeric agents developed, challenges, and future perspectives
Heba M. Hesham, Eman M.E. Dokla, Eman Z. Elrazaz, et al.
European Journal of Medicinal Chemistry (2024) Vol. 277, pp. 116717-116717
Closed Access | Times Cited: 1
Histone deacetylase 8 in focus: Decoding structural prerequisites for innovative epigenetic intervention beyond hydroxamates
Samima Khatun, Indrasis Dasgupta, Sudip Sen, et al.
International Journal of Biological Macromolecules (2024) Vol. 284, pp. 138119-138119
Closed Access | Times Cited: 1
HDAC6 detector: online application for evaluating compounds as potential histone deacetylase 6 inhibitors
O.V. Tinkov, V. Yu. Grigorev, L. D. Grigoreva, et al.
SAR and QSAR in environmental research (2023) Vol. 34, Iss. 8, pp. 619-637
Closed Access | Times Cited: 2
HDACi: The Columbus’ Egg in Improving Cancer Treatment and Reducing Neurotoxicity?
Angelica Squarzoni, Arianna Scuteri, Guido Cavaletti
Cancers (2022) Vol. 14, Iss. 21, pp. 5251-5251
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top